ArticleFrontiers in oncology2014

Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.

Khalid Abubaker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.